Westlake Village-based MannKind saw rising revenue and gave a positive update to its orphan lung pipeline when it announced its earnings for the third quarter of 2024. MannKind, a biotechnology ...

Good afternoon, and welcome to the MannKind Corporation third quarter 2024 financial results earnings call. As a reminder, ...

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have received a consensus recommendation of “Buy” from the seven ...

MannKind Corp (MNKD) reports a 37% revenue increase, driven by Tyvaso DPI and Afrezza, while navigating market challenges and ...

Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is ...

Ofek, Elie, and Amanda Dai. "MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work." Harvard Business School Case 518-031, August 2017. (Revised July 2018.) ...

MannKind will host a conference call and presentation webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast will be accessible via a link on MannKind’s website. A replay will ...

RBC Capital raised the firm’s price target on MannKind (MNKD) to $7 from $5 and keeps a Sector Perform rating on the shares. The company ...

International Assets Investment Management LLC boosted its stake in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 511 ...

This trial was designed to really look at usual care, which is inclusive of automated insulin delivery pumps, mainly tandem and omnipod in this trial as well as patients on MD I comparing that to a ...

Q3 2024 Earnings Call Transcript November 7, 2024 MannKind Corporation beats earnings expectations. Reported EPS is $0.05, ...